New Book from Center for Creative Leadership Redefines Stress and How to Control It
Nov 07, 2016 14:00 pm UTC| Business
GREENSBORO, N.C., Nov. 07, 2016 -- Stress is commonly viewed as inevitable – the unavoidable result of people and situations in the workplace. But this is a false and dangerous assumption, according to a newly...
LifeVantage Expands into Province of Quebec in Canada
Nov 07, 2016 14:00 pm UTC| Business
SALT LAKE CITY, Nov. 07, 2016 -- LifeVantage Corporation (Nasdaq:LFVN), has announced its continued expansion into Canada, and officially began sales activities in the province of Quebec on November 5, 2016. ...
Spectranetics to Attend Upcoming Investor Conferences
Nov 07, 2016 14:00 pm UTC| Business
COLORADO SPRINGS, Colo., Nov. 07, 2016 -- The Spectranetics Corporation (NASDAQ:SPNC), (“the Company”) today announced that company management will be attending three upcoming investor conferences. On November 16th,...
Nov 07, 2016 14:00 pm UTC| Business
NEW YORK, Nov. 07, 2016 -- Hunt Mortgage Group, a leader in financing commercial real estate throughout the United States, announced today that it facilitated the acquisition of a multifamily portfolio located in Tampa,...
Nov 07, 2016 14:00 pm UTC| Business
VALENCIA, Calif., Nov. 07, 2016 -- Wesco Aircraft Holdings, Inc. (NYSE:WAIR), the world’s leading provider of comprehensive supply chain management services to the global aerospace industry, today announced a multi-year...
Nov 07, 2016 14:00 pm UTC| Business
SANTA CLARA, Calif., Nov. 07, 2016 -- Infoblox Inc. (NYSE:BLOX), the network control company that provides Actionable Network Intelligence, today announced the latest release of its software (NIOS 8.0) for DNS, DHCP and...
Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Nov 07, 2016 14:00 pm UTC| Business
Preliminary Efficacy Data from Phase Ib/IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer presented at European Society for Medical Oncology (ESMO) Congress Initiates Stage 2 of the Phase IIa clinical trial...